CERTIFIED TRUE COPY

FILED

FEB 1 1 2004

DOARD OF PHALHACY

PETER C. HARVEY ATTORNEY GENERAL OF NEW JERSEY Division of Law - 5th Floor 124 Halsey Street P.O. Box 45029 Newark, New Jersey 07101

By: Marianne W. Greenwald Deputy Attorney General Tel. No. (973) 648-4876

STATE OF NEW JERSEY
DEPARTMENT OF LAW & PUBLIC SAFETY
DIVISION OF CONSUMER AFFAIRS
STATE BOARD OF PHARMACY

IN THE MATTER OF THE SUSPENSION OR REVOCATION OF THE LICENSE OF

Administrative Action

interim order

ROY THOMAS PESCIOTTA, R.P.

TO PRACTICE PHARMACY IN THE STATE OF NEW JERSEY

This matter was opened to the New Jersey State Board of Pharmacy upon information that on November 13, 2003 respondent was arrested in Dover Township and charged with possession of 25 Oxycodone tablets, marijuans and drug paraphernalia. Respondent represents that he is only in possession of Oxycodone pursuant to valid prescriptions and denies possession of marijuana and drug paraphernalia. (Respondent's treatment records for the year 2003 have been submitted to the Board.)

The Board believes that the requirements set forth in this interim order are adequately protective of the public health,

safety and welfare and will serve to assure the Board that respondent does not engage in substance abuse.

ACCORDINGLY, IT IS on this // day of ALb , 2004,

ORDINED AND AGREED that for six months and two weeks from
the date of entry of this Order:

- sampling a minimum of twice a week which shall include at least one weekend per month, at a laboratory facility approved by the Board. The urine monitoring shall be conducted with direct witnessing of the taking of the samples as designed by the laboratory facility. The initial drug screen shall utilize appropriate screening techniques and all confirming tests and/or secondary tests will be performed by gas/chromatography/mass spectrometry (G.C./M.S.). The testing procedure shall include a forensic chain of custody protocol to ensure sample integrity and to provide documentation in the event of legal challenge.
- Executive Director of the Board, or her designee in the event she is unavailable. The Board also will retain sole discretion to modify the manner of testing in the event technical developments or individual requirements indicate that a different methodology or approach is required in order to guarantee the accuracy and reliability of the testing.

- (c) Any failure by respondent to submit or provide a urine sample within twenty-four (24) hours of a request will be deemed to be equivalent to a confirmed positive urine test. In the event respondent is unable to appear for a scheduled urine test or provide a urine sample due to illness or other impossibility, consent to waive that day's test must be secured from Joanne Boyer, or her designee. Personnel at the lab facility shall not be authorized to waive a urine test. In addition, respondent must provide the Board with written substantiation of his inability to appear for a test within (2) days, e.g., a physician's report attesting that he was so ill that he was unable to provide the urine sample or appear for the test. "Impossibility" as employed in this provision shall mean an obstacle beyond the control of respondent that is so insurmountable or that makes appearance for the test or provision of the urine sample so infeasible that a reasonable person would not withhold consent to waive the test on that day.
 - (d) In the event respondent will be out of the State for any reason, the Board shall be so advised so that arrangements may be made at the Board's discretion for alternate testing. The Board may, in its sole discretion, modify the frequency of testing or method of testing during the monitoring period.

- (e) Any urine test result showing creatinine levels below 20 MG/DL and a specific gravity below 1.003 shall be deamed a confirmed positive urine test.
- (f) Respondent shall familiarize himself with all foods, food additives or other products (such as poppy seeds) which may affect the validity of urine screens, be presumed to possess that knowledge, and shall refrain from the use of such substances. Ingestion of such substances shall not be an acceptable reason for a positive urine screen and/or failure to comply with the urine monitoring program.
- physicians and/or dentists of this Order. Respondent shall causa any physician or dentist who prescribes medication which is a controlled dangerous substance to provide a written report to the Board together with patient records indicating the need for such medication. Such report shall be provided to the Board no later than two (2) days subsequent to the prescription in order to avoid confusion which may be caused by a confirmed positive uring test as a result of such medication.
- and all parties who are participating in the monitoring, treating or other program as outlined in this order, as may be required in order that all reports, records, and other pertinent information may be provided to, and utilized by the Board in a timely manner.

- 4. Respondent hereby consents to the entry of an Order of Automatic Suspension of his license without notice upon the Board's receipt of any reliable information such as, but not limited to, a report of a confirmed positive urine from the party respondible for monitoring respondent's urine, or information from any out-patient program, which reveals evidence of substance abuse during the probationary period.
- of the automatic suspension on two (2) days notice but in such event shall be limited to a showing that urine tested was not his or was a false positive, in the case of urine testing, or that other information submitted was false.
- 6. Any failure to appear for a urine test for which consent is not secured from the Board and for which no written substantiation is furnished satisfactory to the Board within two (2) days of such failure to appear shall be grounds for activation of the suspension upon short notice.

NEW JERSEY STATE BOARD OF PHARMACY

y: Edward

Edward G. McGinley, R.P.

President

I have read the within Order and understand its terms. I consent to the entry of this Order by the New Jersey Board of Pharmack.

Roy Thomas Pesciotta, R.F.